source · text/markdown
source_f30008cdc51e4283
sha256 70c9c496af743f14cf517e9bb765a7e7e4cde713de429003d2ca97fffdd32fc3
by researka:v2 · 2026-06-12 09:16:31.821085+04:00
# Research Synthesis: Metformin Treatment Effects — full paper ## Abstract This paper synthesizes evidence on metformin treatment effects across 56 accepted source papers and 3357 high-confidence extracted claims. The evidence profile contains 6 direct clinical sources, 27 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 484 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the cardiometabolic and contextual adjacent evidence outcome classes, null signals in the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics outcome classes, and negative signals in the cardiometabolic, contextual adjacent evidence, safety and comorbidity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that metformin treatment effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. ## Methods ### Review type and protocol This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-metformin_treatment_effects-v06-DAILY-2026-06-12T04-21-22Z-R2`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-12. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `metformin treatment effects aging` - `metformin treatment effects older adults` - `metformin treatment effects randomized controlled trial` - `metformin treatment aging` - `metformin treatment older adults` - `metformin treatment randomized controlled trial` - `metformin aging` - `metformin older adults` - `metformin randomized controlled trial` ### Eligibility criteria - Sources whose primary content addresses metformin treatment effects. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 176 records in the receipt-candidate union, 56 were classified as source candidates and 56 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | Receipt candidate union | 176 | | Classified source candidates | 56 | | No extractable claims | 17 | | None-only claim binding | 5 | | Mixed partial-or-none claim-binding candidates | 54 | | Partial-only claim-binding candidates | 20 | | Strict high-confidence sources | 24 | | Admitted final sources | 56 | ### Exclusion reasons - Non-traceable findings (claim could not be linked to source text): 0 records. - Wrong population / off-topic sources excluded at screening. - Duplicate records deduplicated by DOI / PMID before screening. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, cognitive, contextual adjacent evidence, dosing and pharmacokinetics, immune and inflammation, longevity, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. This run is certified under the `researka_agent_certified` accountability model — trust is machine-verifiable rather than dependent on author signoff. ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Contextual Adjacent Evidence | n=27; claims=1160 | no extracted directional signal in 18/27 sources | 1 direct; 16 indirect; 10 review | limited corpus depth in this outcome class | | Cardiometabolic | n=18; claims=1662 | no extracted directional signal in 7/18 sources | 5 direct; 6 indirect; 7 review | limited corpus depth in this outcome class | | Dosing and Pharmacokinetics | n=3; claims=245 | no extracted directional signal in 2/3 sources | 1 indirect; 2 review | limited corpus depth in this outcome class | | Safety and Comorbidity | n=3; claims=110 | no extracted directional signal in 2/3 sources | 2 indirect; 1 review | limited corpus depth in this outcome class | | Cognitive | n=1; claims=2 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | | Immune and Inflammation | n=1; claims=79 | unclear signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | | Longevity | n=1; claims=80 | mixed signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | | Safety | n=1; claims=3 | unclear signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | | Skeletal, Fracture, and Bone | n=1; claims=16 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate. ### Contextual Adjacent Evidence Outcomes 27 included sources were assigned to this outcome class. Directional coding: negative=1, null=18, positive=1, unclear=7. Directness coding: direct=1, indirect=16, review=10. ### Cardiometabolic Outcomes 18 included sources were assigned to this outcome class. Directional coding: mixed=3, negative=4, null=7, positive=2, unclear=2. Directness coding: direct=5, indirect=6, review=7. ### Dosing Pharmacokinetics Outcomes 3 included sources were assigned to this outcome class. Directional coding: null=2, unclear=1. Directness coding: indirect=1, review=2. ### Safety Comorbidity Outcomes 3 included sources were assigned to this outcome class. Directional coding: negative=1, null=2. Directness coding: indirect=2, review=1. ### Cognitive Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1. ### Immune Inflammation Outcomes 1 included source were assigned to this outcome class. Directional coding: unclear=1. Directness coding: indirect=1. ### Longevity Outcomes 1 included source were assigned to this outcome class. Directional coding: mixed=1. Directness coding: review=1. ### Safety Outcomes 1 included source were assigned to this outcome class. Directional coding: unclear=1. Directness coding: review=1. ### Skeletal Fracture Bone Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The curated corpus is dominated by sources in which metformin is used as background or add-on therapy rather than as the randomized intervention under test, and this constrains what the headline conclusions can support. In Hong 2026, Seo 2026, Lee 2026, Lim 2026, Zaveri 2026, Mohan 2026, and Kim 2026, metformin is the comparator floor or backbone to which a new agent (pioglitazone 30 mg, lobeglitazone 0.5 mg, empagliflozin, sitagliptin+empagliflozin FDC, sitagliptin+glimepiride FDC, glimepiride+voglibose, or a fourth oral drug) is added. Across those records, between-group p-values are routinely <0.0001 or <0.001, but the contrast is rarely metformin-vs-placebo. Conclusions about metformin monotherapy efficacy and durability therefore rest on indirect inference, not on within-corpus metformin-vs-placebo arms. The single RCT that randomizes metformin vs another glucose-lowering agent head-to-head in this bundle is Lim 2026b (empagliflozin vs metformin in drug-naïve T2D, HbA1c change −0.78% on metformin), and that single source is the only one that anchors a direct monotherapy estimate in the corpus. Several clinically relevant claims are touched by only one source, which means they cannot be replicated within the corpus. The colorectal-neoplasm primary-prevention estimate (Shen 2025) is similarly single-source, and the chronic-kidney-disease safety signal in very elderly T2D patients (Marchini 2026) rests on one observational cohort with three p-values (0.013, 0.002, 0.001). The MET-PREVENT sarcopenia/prefrailty proof-of-concept (Rennie 2022), the MET-PCOS optimisation trial in PCOS (Hautamaki 2026), the EMERGE gestational-diabetes mother-and-child cohort (Scairati 2026), and the FIBROMET phase II in primary myelofibrosis (Campos 2025) are each represented by a single record. Any cross-record replication of these findings would require sources outside the admitted bundle. The population specificity of the admitted sources limits the external validity of any pooled inference. The cardiometabolic backbone of the corpus is overwhelmingly Asian (Korean, Chinese, Indian) T2D populations: Hong 2026, Seo 2026, Lee 2026, Lim 2026, Lim 2026b, Zaveri 2026, Mohan 2026, Rattarasarn 2026, and Guo 2026 all enroll East- or South-Asian T2D patients. Pregnant and postpartum populations are covered only via Brinkmann 2025 (GDM maternal/neonatal safety) and Scairati 2026/Newman 2026 (EMERGE secondary analyses). Long-term mortality RCTs in non-diabetic, community-dwelling older adults — the population that would matter most for any 'anti-aging' inference — are not represented in the corpus. ## Conclusion For metformin treatment effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. ## What This Synthesis Adds This synthesis maps 56 included sources on Metformin Treatment Effects across 9 outcome classes and 484 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. Across 56 curated reference papers, the evidence base for Metformin Treatment Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Metformin Treatment Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest unresolved contrast is the disagreement between Seo 2026 and Malin 2026 on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over. Prior reviews in the corpus (Malik 2026, Hamsho 2026, Zhang 2026, Lim 2026b, Kao 2026) emphasize convergent signals on Metformin Treatment Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | longevity | 0 | 1 | mixed | direct interventional hard-endpoint gap | | cognitive | 0 | 1 | null | direct interventional hard-endpoint gap | | safety | 0 | 1 | unclear | direct interventional hard-endpoint gap | | cardiometabolic | 5 | 13 | mixed, negative, null, positive, unclear | conflict-resolution gap | | dosing and pharmacokinetics | 0 | 3 | null, unclear | direct interventional hard-endpoint gap | | safety and comorbidity | 0 | 3 | negative, null | direct interventional hard-endpoint gap | | immune and inflammation | 0 | 1 | unclear | direct interventional hard-endpoint gap | | skeletal, fracture, and bone | 0 | 1 | null | direct interventional hard-endpoint gap | | contextual adjacent evidence | 1 | 26 | negative, null, positive, unclear | conflict-resolution gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: mixed | | P2 | cognitive: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | | P3 | safety: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear | | P4 | cardiometabolic: conflict-resolution gap | 5 direct and 13 indirect sources; direction profile: mixed, negative, null, positive, unclear | | P5 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear | ### Next-Study Design Recommendation The next high-yield study for Metformin Treatment Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot Source directness breakdown: 6/56 retained sources directly address the stated topic and aging-relevant hard endpoints; 50/56 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims. ### Source Classification Map - Zaveri 2026: outcome=Cardiometabolic; directness=indirect; tier=B2. - Hong 2026: outcome=Cardiometabolic; directness=direct; tier=A1. - Guo 2026: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2. - Lee 2026: outcome=Cardiometabolic; directness=indirect; tier=B2. - Seo 2026: outcome=Cardiometabolic; directness=direct; tier=A1. - Malik 2026: outcome=Cardiometabolic; directness=review; tier=B1. - Sahay 2026: outcome=Dosing and Pharmacokinetics; directness=review; tier=B2. - Lim 2026: outcome=Cardiometabolic; directness=direct; tier=A1. The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Hong 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.0001. - Seo 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.001. - Lim 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null; representative statistic=P < 0.0001. - Ratajczak 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null; representative statistic=P < 0.01. - Mashhadi 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.001. - Kim 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.002. - Malik 2026; tier=B1; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.0001. - Hamsho 2026; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=negative; representative statistic=P < 0.0001. - Zhang 2026; tier=B1; directness=review; endpoint=longevity; direction=mixed; representative statistic=P < 0.00001. - Lim 2026b; tier=B1; directness=review; endpoint=cardiometabolic; direction=negative; representative statistic=P = 0.049. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=172. - Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=159. - Efficacy and Safety of Fixed‐Dose Combinations of Sitagliptin and Empagliflozin as Add‐On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Multi‐Centre, Placebo‐Controlled, Phase III Trial: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=134. - Multi-strain probiotic reduces gastrointestinal side effects in women with elevated HOMA-IR index treated with metformin: a 12-week randomised controlled trial: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=57. - Effects of Ziziphus jujuba, metformin, and myoinositol on pregnancy rates and metabolic parameters in infertile women with PCOS: a randomized controlled trial: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=17. - Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial.: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=7. - Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=153. - Effects of probiotic and metformin co-administration versus metformin monotherapy on anthropometric measurements, hormones, and glucolipid profile in women with polycystic ovary syndrome: a systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=negative; claims=87. - Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=80. - Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-naïve type 2 diabetes: The EMPA-FIT study.: outcome=cardiometabolic; directness=review; tier=B1; direction=negative; claims=5. - The efficacy of metformin for pain, function, and quality of life in knee osteoarthritis: A systematic review and meta-analysis.: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=4. - Metformin for knee osteoarthritis in overweight and obese adults: a systematic review and meta-analysis of efficacy, safety, and disease-modifying anti-inflammatory potential.: outcome=safety; directness=review; tier=B1; direction=unclear; claims=3. - Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=2. - Effectiveness of metformin in the management of osteoarthritis in patients with type 2 diabetes.: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=1. - GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes: outcome=cardiometabolic; directness=indirect; tier=B2; direction=negative; claims=246. - HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=170. - Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=167. - Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=144. - Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study: outcome=cardiometabolic; directness=indirect; tier=B2; direction=negative; claims=132. - Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=124. - Associations of modifiable preconception, pregnancy and postpartum factors with health outcomes for women with type 2 diabetes and their children: A systematic review and meta‐analysis of observational studies: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=115. - Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta‐Analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=positive; claims=106. - Impact of metformin on melanoma: a meta-analysis and systematic review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=103. - EMERGE Mothers and Kids: a longitudinal cohort study of mothers and children enrolled in the randomized placebo-controlled trial of metformin in women with GDM (EMERGE): study protocol: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=83. - Metformin increases glycolysis and the stress-induced cytokine GDF15 but not FGF21 in humans: outcome=immune inflammation; directness=indirect; tier=B2; direction=unclear; claims=79. - Effectiveness and safety of auricular therapy for polycystic ovary syndrome: a systematic review and meta-analysis: outcome=cardiometabolic; directness=review; tier=B2; direction=mixed; claims=79. - Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=69. - Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=64. - Metformin for primary prevention of colorectal neoplasms in adenoma-free populations: a systematic review and dose-response meta-analysis: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=unclear; claims=64. - Efficacy and safety of traditional Chinese classic prescriptions combined with metformin in the treatment of type 2 diabetes mellitus: a Bayesian network meta-analysis: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=52. - The role of male foetal sex on maternal and neonatal outcomes in pregnancies complicated by gestational diabetes—secondary analysis of a randomised placebo controlled clinical trial of metformin in gestational diabetes (EMERGE): outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=52. - Effects of Premeal Versus Postmeal Metformin Administration on Postmeal Glycemic Control in Individuals With Type 2 Diabetes Mellitus: A Randomized, 8‐Week Crossover Study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=52. - The Impact of Metformin on Vitamin B12 Levels in Children and Adolescents: A Systematic Review and Single‐Arm Meta‐Analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=49. - Metformin safety during pregnancy in women with gestational diabetes mellitus: A systematic review and meta‐analysis of maternal, neonatal and long‐term outcomes: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=48. - The Impact of Different Oral Antidiabetic Drugs on Insulin Pump Intensive Therapy in Type 2 Diabetes Patients: A Clinical Study: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=44. - Effects of short‐term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP ‐ ELM study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=41. - SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register‐based randomised trial on prevention of diabetic complications: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=40. - Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=40. - Bioequivalence assessment between two formulations of a film-coated fixed-dose combination of metformin and vildagliptin (850/50mg) in healthy Tunisian subjects under fed conditions: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=37. - Efficacy of metformin as an adjuvant therapy in gynecologic malignancies: a meta-analysis of randomized controlled trials: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=37. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Severity 5 disagreement: Seo 2026 vs Malin 2026; Seo 2026 (negative) vs Malin 2026 (positive) on cardiometabolic - Severity 5 disagreement: Seo 2026 vs Kim 2026; Seo 2026 (negative) vs Kim 2026 (positive) on cardiometabolic - Severity 5 disagreement: Zaveri 2026 vs Malin 2026; Zaveri 2026 (negative) vs Malin 2026 (positive) on cardiometabolic - Severity 5 disagreement: Zaveri 2026 vs Kim 2026; Zaveri 2026 (negative) vs Kim 2026 (positive) on cardiometabolic - Severity 5 disagreement: Malin 2026 vs Mohan 2026; Malin 2026 (positive) vs Mohan 2026 (negative) on cardiometabolic - Severity 5 disagreement: Malin 2026 vs Lim 2026b; Malin 2026 (positive) vs Lim 2026b (negative) on cardiometabolic - Severity 5 disagreement: Hamsho 2026 vs Ashraf 2026; Hamsho 2026 (negative) vs Ashraf 2026 (positive) on contextual other - Severity 5 disagreement: Mohan 2026 vs Kim 2026; Mohan 2026 (negative) vs Kim 2026 (positive) on cardiometabolic Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Schoenaker 2026, Feng 2024, Li 2026, Kolnes 2026, Szymczak-Pajor 2026, Kimura-Medorima 2026, Che 2026, Tahir 2026, Peng 2026, Miyamoto 2026, Eriksson 2025, Ferchichi 2026, Zhang 2026b, Briata 2025, Hiu 2026, Yu 2026, Petrocelli 2023, Yan 2026, Damkier 2026, Jimoh 2026, Chen 2025, Othman 2026, McCreight 2016, Rena 2017, Chenchula 2026, Mahoon 2026, Shi 2026, Chen 2026, Ioannidis 2005. Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Pragmatic 2035, ADA 2024. ## References - **Zaveri 2026.** _GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes._ PLOS One, 2026. DOI: 10.1371/journal.pone.0337107. PMID: 41650186. - **Hong 2026.** _Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial._ Diabetes & Metabolism Journal, 2026. DOI: 10.4093/dmj.2024.0696. PMID: 41151541. - **Guo 2026.** _HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin._ JAMA Network Open, 2026. DOI: 10.1001/jamanetworkopen.2026.15622. PMID: 42234428. - **Lee 2026.** _Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70386. PMID: 41417560. - **Seo 2026.** _Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70257. PMID: 41236870. - **Malik 2026.** _Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis._ Medicine, 2026. DOI: 10.1097/MD.0000000000049050. PMID: 42216339. - **Sahay 2026.** _Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70778. PMID: 42070788. - **Lim 2026.** _Efficacy and Safety of Fixed‐Dose Combinations of Sitagliptin and Empagliflozin as Add‐On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Multi‐Centre, Placebo‐Controlled, Phase III Trial._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70669. PMID: 41883295. - **Mohan 2026.** _Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study._ Journal of Diabetes, 2026. DOI: 10.1111/1753-0407.70217. PMID: 41979234. - **Malin 2026.** _Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70478. PMID: 41532329. - **Schoenaker 2026.** _Associations of modifiable preconception, pregnancy and postpartum factors with health outcomes for women with type 2 diabetes and their children: A systematic review and meta‐analysis of observational studies._ Diabetic Medicine, 2026. DOI: 10.1111/dme.70183. PMID: 41354939. - **Ashraf 2026.** _Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta‐Analysis._ Endocrinology, Diabetes & Metabolism, 2026. DOI: 10.1002/edm2.70238. PMID: 42120997. - **Feng 2024.** _Impact of metformin on melanoma: a meta-analysis and systematic review._ Frontiers in Oncology, 2024. DOI: 10.3389/fonc.2024.1399693. PMID: 38846983. - **Hamsho 2026.** _Effects of probiotic and metformin co-administration versus metformin monotherapy on anthropometric measurements, hormones, and glucolipid profile in women with polycystic ovary syndrome: a systematic review and meta-analysis._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1802369. PMID: 41970993. - **Scairati 2026.** _EMERGE Mothers and Kids: a longitudinal cohort study of mothers and children enrolled in the randomized placebo-controlled trial of metformin in women with GDM (EMERGE): study protocol._ Trials, 2026. DOI: 10.1186/s13063-026-09703-6. PMID: 42010697. - **Zhang 2026.** _Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1815219. PMID: 42087873. - **Li 2026.** _Effectiveness and safety of auricular therapy for polycystic ovary syndrome: a systematic review and meta-analysis._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1726938. PMID: 41858851. - **Kolnes 2026.** _Metformin increases glycolysis and the stress-induced cytokine GDF15 but not FGF21 in humans._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1797525. PMID: 41928890. - **Szymczak-Pajor 2026.** _Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?._ International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27104195. PMID: 42196179. - **Shen 2025.** _Metformin for primary prevention of colorectal neoplasms in adenoma-free populations: a systematic review and dose-response meta-analysis._ Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1645387. PMID: 41347173. - **Kimura-Medorima 2026.** _Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial._ Cardiovascular Diabetology, 2026. DOI: 10.1186/s12933-026-03142-y. PMID: 41888924. - **Ratajczak 2026.** _Multi-strain probiotic reduces gastrointestinal side effects in women with elevated HOMA-IR index treated with metformin: a 12-week randomised controlled trial._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1765741. PMID: 41852479. - **Che 2026.** _Efficacy and safety of traditional Chinese classic prescriptions combined with metformin in the treatment of type 2 diabetes mellitus: a Bayesian network meta-analysis._ Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2026.1693378. PMID: 41756240. - **Newman 2026.** _The role of male foetal sex on maternal and neonatal outcomes in pregnancies complicated by gestational diabetes—secondary analysis of a randomised placebo controlled clinical trial of metformin in gestational diabetes (EMERGE)._ BMC Medicine, 2026. DOI: 10.1186/s12916-026-04778-z. PMID: 41820921. - **Rattarasarn 2026.** _Effects of Premeal Versus Postmeal Metformin Administration on Postmeal Glycemic Control in Individuals With Type 2 Diabetes Mellitus: A Randomized, 8‐Week Crossover Study._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70768. PMID: 41994908. - **Tahir 2026.** _The Impact of Metformin on Vitamin B12 Levels in Children and Adolescents: A Systematic Review and Single‐Arm Meta‐Analysis._ Endocrinology, Diabetes & Metabolism, 2026. DOI: 10.1002/edm2.70232. PMID: 42144864. - **Brinkmann 2025.** _Metformin safety during pregnancy in women with gestational diabetes mellitus: A systematic review and meta‐analysis of maternal, neonatal and long‐term outcomes._ Diabetic Medicine, 2025. DOI: 10.1111/dme.70173. PMID: 41354637. - **Peng 2026.** _The Impact of Different Oral Antidiabetic Drugs on Insulin Pump Intensive Therapy in Type 2 Diabetes Patients: A Clinical Study._ Journal of Diabetes Research, 2026. DOI: 10.1155/jdr/9957473. PMID: 41913696. - **Miyamoto 2026.** _Effects of short‐term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP ‐ ELM study._ Journal of Diabetes Investigation, 2026. DOI: 10.1111/jdi.70245. PMID: 41615833. - **Eriksson 2025.** _SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register‐based randomised trial on prevention of diabetic complications._ Diabetes, Obesity & Metabolism, 2025. DOI: 10.1111/dom.70320. PMID: 41311237. - **Hautamaki 2026.** _Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial._ BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-115656. PMID: 41819580. - **Ferchichi 2026.** _Bioequivalence assessment between two formulations of a film-coated fixed-dose combination of metformin and vildagliptin (850/50mg) in healthy Tunisian subjects under fed conditions._ Scientific Reports, 2026. DOI: 10.1038/s41598-025-34082-4. PMID: 41651891. - **Zhang 2026b.** _Efficacy of metformin as an adjuvant therapy in gynecologic malignancies: a meta-analysis of randomized controlled trials._ Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2026.1752095. PMID: 41988534. - **Briata 2025.** _Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis._ Cancer Prevention Research (Philadelphia, Pa.), 2025. DOI: 10.1158/1940-6207.CAPR-25-0104. PMID: 41165048. - **Hiu 2026.** _Applying a hypothetical strategy to the intercurrent event of non-adherence with the parametric g-formula: a post hoc secondary analysis of the MET-PREVENT randomised controlled trial._ Trials, 2026. DOI: 10.1186/s13063-026-09708-1. PMID: 41957819. - **Marchini 2026.** _Metformin Use and Clinical Outcomes in Very Elderly Patients with Type 2 Diabetes and Chronic Kidney Disease._ Medicina, 2026. DOI: 10.3390/medicina62040776. PMID: 42075647. - **Yu 2026.** _The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1780676. PMID: 42064764. - **Rennie 2022.** _MET-PREVENT: metformin to improve physical performance in older people with sarcopenia and physical prefrailty/frailty – protocol for a double-blind, randomised controlled proof-of-concept trial._ BMJ Open, 2022. DOI: 10.1136/bmjopen-2022-061823. PMID: 35851031. - **Petrocelli 2023.** _Disuse‐induced muscle fibrosis, cellular senescence, and senescence‐associated secretory phenotype in older adults are alleviated during re‐ambulation with metformin pre‐treatment._ Aging Cell, 2023. DOI: 10.1111/acel.13936. PMID: 37486024. - **Yan 2026.** _Circulating Profiles of the Bile Acid Metabolomics in Patients With Polycystic Ovary Syndrome Treated With Metformin or Canagliflozin._ Pharmacotherapy, 2026. DOI: 10.1002/phar.70092. PMID: 41401816. - **Damkier 2026.** _Paternal use of metformin and risk of major congenital malformations: A meta‐analysis of 4 studies._ British Journal of Clinical Pharmacology, 2026. DOI: 10.1002/bcp.70547. PMID: 41937475. - **Mashhadi 2026.** _Effects of Ziziphus jujuba, metformin, and myoinositol on pregnancy rates and metabolic parameters in infertile women with PCOS: a randomized controlled trial._ Journal of Ovarian Research, 2026. DOI: 10.1186/s13048-025-01867-0. PMID: 41618368. - **Campos 2025.** _Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial._ Hematological Oncology, 2025. DOI: 10.1002/hon.70163. PMID: 41456173. - **Kim 2026.** _Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial._ Diabetes Obes Metab, 2026. DOI: 10.1111/dom.70527. PMID: 41630635. - **Jimoh 2026.** _Comparative Efficacy, Safety, and Cost‐Utility of DPP‐4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real‐World Clinical and Economic Outcomes._ Journal of Diabetes Research, 2026. DOI: 10.1155/jdr/8464330. PMID: 41925338. - **Chen 2025.** _Randomized controlled trial of effects of metformin in NAFLD patients with newly diagnosed type 2 diabetes treated with an intensive lifestyle: a study protocol._ Trials, 2025. DOI: 10.1186/s13063-025-09191-0. PMID: 41174662. - **Othman 2026.** _Metformin for asthma exacerbations._ The Cochrane Database of Systematic Reviews, 2026. DOI: 10.1002/14651858.CD016177. PMID: 41631535. - **Lim 2026b.** _Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-naïve type 2 diabetes: The EMPA-FIT study._ J Diabetes Complications, 2026. DOI: 10.1016/j.jdiacomp.2025.109214. PMID: 41223492. - **McCreight 2016.** _Metformin and the gastrointestinal tract._ Diabetologia, 2016. DOI: 10.1007/s00125-015-3844-9. PMID: 26780750. - **Rena 2017.** _The mechanisms of action of metformin._ Diabetologia, 2017. DOI: 10.1007/s00125-017-4342-z. PMID: 28776086. - **Kao 2026.** _The efficacy of metformin for pain, function, and quality of life in knee osteoarthritis: A systematic review and meta-analysis._ Semin Arthritis Rheum, 2026. DOI: 10.1016/j.semarthrit.2025.152908. PMID: 41506068. - **Chenchula 2026.** _Metformin for knee osteoarthritis in overweight and obese adults: a systematic review and meta-analysis of efficacy, safety, and disease-modifying anti-inflammatory potential._ Inflammopharmacology, 2026. DOI: 10.1007/s10787-026-02218-1. PMID: 42043713. - **Pragmatic 2035.** _Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients._ 2035. Identifier unavailable; no DOI or PMID in source metadata. - **Mahoon 2026.** _The Role of Antidiabetic Therapies in Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review of Metformin, Pioglitazone, and GLP-1 Receptor Agonists._ International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27093967. PMID: 42123553. - **Shi 2026.** _Association between preoperative metformin exposure and postoperative nausea and vomiting in patients undergoing general anaesthesia: a protocol for a prospective observational cohort study in a Chinese tertiary hospital._ BMJ Open, 2026. DOI: 10.1136/bmjopen-2026-117537. PMID: 42215267. - **Chen 2026.** _Effectiveness of metformin in the management of osteoarthritis in patients with type 2 diabetes._ Clin Rheumatol, 2026. DOI: 10.1007/s10067-026-07970-x. PMID: 41649758. ### Background References *Canonical clinical thresholds cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).* - **ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006. - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.
metadata
{
"article_type": "evidence_map",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "ee61e5c4-f17e-4dd4-889e-663a3f99015a",
"title": "Research Synthesis: Metformin Treatment Effects \u2014 full paper"
}